Amgen Inc. Stock Performance
Amgen Inc. shares closed at $466.01, reflecting a single-session decline of approximately 2.5%, per SID market data. Despite this pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 14.42% over the past month, 23.0% over three months, and 41.14% over the trailing twelve months. The 50-day moving average stands at $419.96, while the 200-day moving average sits at $377.29, placing the current price well above both key technical levels according to Massive/Polygon data. The 14-day relative strength index registers at 76.0, positioning the stock in overbought territory above the conventional 70 threshold. Amgen's beta of 0.472 indicates substantially lower volatility relative to the broader market, consistent with its defensive healthcare sector positioning. Average daily trading volume stands at approximately 2.89 million shares, supporting a market capitalization of roughly $209.2 billion.
Amgen Inc. Valuation Analysis
Amgen Inc. currently trades at a price-to-earnings ratio of 27.13, which represents a premium relative to the broader healthcare sector, according to SID market data. The PEG ratio stands at approximately 2.72, suggesting the stock's earnings growth rate does not fully justify its elevated P/E multiple at current levels. The price-to-book ratio is notably high at 24.16, reflecting Amgen's asset-light biotechnology business model and significant accumulated goodwill from prior acquisitions, per SEC filings. The company offers a forward dividend yield of approximately 2.49%, providing an income component that differentiates it from many growth-oriented biotech peers. With a market capitalization of $209.2 billion, Amgen ranks among the largest biotechnology companies globally. These valuation metrics collectively position Amgen at a premium to historical norms, coinciding with the stock's 41.14% appreciation over the trailing twelve-month period as reflected in current pricing data.
Smart Money Activity for AMGN
Amgen Inc. registers a composite smart money score of 51 out of 100, indicating a neutral overall signal, per SID market data. Institutional ownership receives a perfect score of 25 out of 25, reflecting strong conviction from major fund managers and pension funds as documented in 13F institutional filings. Congressional trading activity scores 8.8 out of 25, while dark pool activity registers at 8.5 out of 25, both contributing modestly to the composite reading. Insider activity scores 8.6 out of 25, with SEC Form 4 filings revealing 15 insider transactions over the past 90 days. Notably, insider buys outnumber sells at 9 purchases versus 6 dispositions, a ratio that leans modestly positive for a large-cap biotechnology company where insider selling often predominates due to equity compensation structures. The divergence between maximum institutional confidence and moderate scores across other categories results in the overall neutral smart money classification for Amgen shares.
Amgen Inc. Earnings Outlook
Amgen Inc. has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $5.29 against analyst estimates of $4.75, representing a positive surprise of $0.54. The following quarter saw EPS of $5.15 versus expectations of $4.76, a $0.39 beat, while the subsequent period produced EPS of $6.29 compared to the $5.60 consensus, yielding a $0.69 surprise. This pattern of accelerating beat magnitudes signals operational execution above market expectations. Looking ahead, analyst estimates project next-quarter earnings of $5.78 per share, with results expected on November 3, per analyst estimates. The consistent outperformance across recent periods has contributed to the stock's 41.14% trailing twelve-month appreciation. Investors will monitor whether Amgen can sustain this trajectory of exceeding consensus forecasts amid its expanding product portfolio.
Wall Street Analyst Ratings for AMGN
Recent Wall Street analyst activity on Amgen Inc. reflects a predominantly neutral-to-cautious consensus, per SID consensus data. On October 23, Oppenheimer reiterated its Outperform rating, representing the sole bullish call among the most recent coverage updates. Barclays maintained its Equal-Weight rating on October 21, while Guggenheim held its Neutral stance on October 13, according to Wall Street analyst reports. Wells Fargo and BMO Capital both reiterated market-neutral positions on October 12, with Equal-Weight and Market Perform ratings respectively. Notably, none of the five most recent analyst actions involved a rating change, with all five maintaining prior classifications. This uniformity suggests the analyst community has largely priced in Amgen's recent earnings outperformance and 23.0% three-month price appreciation. The prevalence of hold-equivalent ratings from four of five covering firms indicates Wall Street views the current $466.01 share price as approaching fair value following the stock's significant run higher over the past year.
